AstraZeneca’s elecoglipron (ECC5004/AZD5004), an oral GLP-1 receptor agonist licensed from Eccogene, generated positive Phase 2 results in both obesity and type 2 diabetes. The company said the studies (VISTA and SOLSTICE) met primary endpoints, supporting advancement to Phase 3 and highlighting elecoglipron as a potential oral backbone for broader cardiometabolic combinations.